A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Clinical trial NCT00446602 · WITHDRAWN
Trial details
- NCT number
- NCT00446602
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.